Italia markets open in 3 hours 36 minutes

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
124,47+1,31 (+1,06%)
Alla chiusura: 04:00PM EST
122,54 -1,93 (-1,55%)
Dopo ore: 04:13PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente123,16
Aperto123,59
Denaro120,90 x 800
Lettera127,51 x 1000
Min-Max giorno122,30 - 125,33
Intervallo di 52 settimane61,28 - 134,08
Volume945.001
Media Volume946.698
Capitalizzazione10,926B
Beta (5 anni mensile)1,01
Rapporto PE (ttm)N/D
EPS (ttm)-4,28
Prossima data utili27 feb 2023 - 03 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A151,00
  • GlobeNewswire

    Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues

    - The Company expects to exceed 2022 full-year guidance for net product revenues - Preliminary net product revenues for the fourth quarter and full-year 2022 are expected to total $235.5 million and $843.3 million, respectively - Preliminary year-end 2022 cash balance of approximately $2.0 billion CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and

  • GlobeNewswire

    Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023 at 1:30 p.m. E.T. / 10:30 a.m. P.T. Following the presentation there will be a Q&A session starting at 1:50 p.m. E.T. / 10:50 a.m. P.T. The presentation will be webcast live under the E

  • GlobeNewswire

    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 13 individuals hired by Sarepta in December 2022. The equity awards were approved in accordance with Nasdaq Listin